Reimbursement Trends and Evidence Requirements for Ultra-Orphan Therapies Across Europe: Optimising Market Access in Increasingly Challenging Markets.
نویسندگان
چکیده
Total Morawski JH1, Paul A2, Spinner DS2, Doyle JJ3, Faulkner EC4, Ransom JF1 1 Quintiles Consulting, Hawthorne, NY, USA; 2 Quintiles Consulting, Durham, NC, USA; 3 Department of Epidemiology and the Department of Healthcare Policy & Management at the Mailman School of Public Health, Columbia University, NY, USA; 4 Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, NC, USA Reimbursement Trends and Evidence Requirements for Ultra-Orphan Disease Therapies Across Europe: Optimising Market Access in Increasingly Challenging Markets
منابع مشابه
Pricing and Market Access of Orphan Drugs in Asia: a Comparative Study Across Growth Markets.
• With the majority of the world’s population, a large number of patients with rare diseases and relatively limited access to appropriate medicines compared with western countries, Asia represents a real opportunity for the commercialisation of orphan drugs • However, despite some countries implementing policy to facilitate this process, funding for orphan drugs remains challenging since health...
متن کاملThe correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
BACKGROUND The aim of this study was to review and compare types of reimbursement recommendations for orphan drugs issued by eight European health technology assessment (HTA) agencies and the reimbursement status of these drugs in the corresponding countries. Separate calculations were also performed for three sub-groups: ultra-orphan drugs, oncology orphan drugs and other (non-ultra, non-oncol...
متن کاملProposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industry
In Poland, two proposed amendments to the reimbursement act are currently in preparation; these are likely to substantially change the pricing and reimbursement landscape for both drugs and medical devices. Proposed changes include: alignment of medical device reimbursement with that of pharmaceuticals; relaxing the strict reimbursement criteria for ultra-orphan drugs; establishment of an addit...
متن کاملPricing and reimbursement of novel oncology drugs in Sweden
We read with great interest the article by Cohen and Felix (1) concerning reimbursement restrictions on orphan drugs. We agree with their concerns that orphan drugs are often met with reimbursement restrictions, but data on the relationship between orphan status and pricing and reimbursement outcomes are scarce. Furthermore, regional disparities within Europe are likely to be significant, contr...
متن کاملDrugs for exceptionally rare diseases: do they deserve special status for funding?
Ultra-orphan drugs are medicines used to treat exceptionally rare diseases that are chronically debilitating or life-threatening. Low patient numbers make it difficult for pharmaceutical companies to recoup research and development costs, and consequently these medicines are generally expensive on a per patient basis. European Union (EU) regulations promote the development of orphan drugs; but ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
دوره 17 7 شماره
صفحات -
تاریخ انتشار 2014